Long-term extension studies and observational drug registers have revealed an increased risk of serious infections in patients treated with anti-tumor necrosis factor agents, particularly infliximab, etanercept and adalimumab. The same may be true for the newer biological drugs rituximab, tocilizumab and abatacept, although this has yet to be confirmed by long-term observational studies. We review the risk of tuberculosis, herpes zoster and other opportunistic infections, and the recommendations for screening for tuberculosis and hepatitis B and C infections in patients with rheumatoid arthritis, with the aim of informing patients and encouraging greater awareness among physicians.

Infections and Biological Therapy in Patients with Rheumatic Diseases / F. Atzeni, A. Batticciotto, I.F. Masala, R. Talotta, M. Benucci, P. Sarzi-Puttini. - In: ISRAEL MEDICAL ASSOCIATION JOURNAL. - ISSN 1565-1088. - 18:3-4(2016 Mar), pp. 164-167.

Infections and Biological Therapy in Patients with Rheumatic Diseases

A. Batticciotto;R. Talotta;P. Sarzi-Puttini
2016

Abstract

Long-term extension studies and observational drug registers have revealed an increased risk of serious infections in patients treated with anti-tumor necrosis factor agents, particularly infliximab, etanercept and adalimumab. The same may be true for the newer biological drugs rituximab, tocilizumab and abatacept, although this has yet to be confirmed by long-term observational studies. We review the risk of tuberculosis, herpes zoster and other opportunistic infections, and the recommendations for screening for tuberculosis and hepatitis B and C infections in patients with rheumatoid arthritis, with the aim of informing patients and encouraging greater awareness among physicians.
Antirheumatic Agents; Certolizumab Pegol; Drug Therapy, Combination; Humans; Infection; Infliximab; Interleukin-6; Rheumatic Diseases; Severity of Illness Index; Tumor Necrosis Factor-alpha; Biological Therapy
Settore MED/16 - Reumatologia
mar-2016
https://www.ima.org.il/FilesUpload/IMAJ/0/193/96910.pdf
Article (author)
File in questo prodotto:
File Dimensione Formato  
infections.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 120.59 kB
Formato Adobe PDF
120.59 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/640569
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 26
  • ???jsp.display-item.citation.isi??? 21
social impact